Pharmacologic Ascorbate in Myeloma Treatment: Doses Matter

@inproceedings{Violet2017PharmacologicAI,
  title={Pharmacologic Ascorbate in Myeloma Treatment: Doses Matter},
  author={Pierre-Christian Violet and Mark Levine},
  booktitle={EBioMedicine},
  year={2017}
}
Ascorbic acid (vitamin C) has followed opaque paths in treating pharmacologic ascorbate. Because myeloma cells are iron-rich, increasmultiplemyeloma, and othermalignancies. Inmyeloma cells, ascorbate surprisingly depleted glutathione and potentiated arsenate trioxide efficacy. Because oral ascorbate at 1 g produces plasma saturation, this dose was selected with arsenate. Predictably, in small trials there was neither benefit nor harm (Rollig and Illmer, 2009; Parrow et al., 2013). Concurrently… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-9 of 9 references

Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice.

Proceedings of the National Academy of Sciences of the United States of America • 2008
View 5 Excerpts

Similar Papers

Loading similar papers…